

PRIOR AUTHORIZATION CRITERIA

DRUG CLASS (ADHD) AGENTS **ATTENTION DEFICIT HYPERACTIVITY DISORDER**

BRAND NAME (generic)

AMPHETAMINES:

**ADZENYS (ALL PRODUCTS)
(amphetamine)**

**DYANAVEL (ALL PRODUCTS)
(amphetamine)**

**EVEKEO (ALL PRODUCTS)
(amphetamine)**

AMPHETAMINE MIXTURES:

**ADDERALL (ALL PRODUCTS)
(amphetamine mixture)**

**MYDAYIS (ALL PRODUCTS)
(amphetamine mixture)**

DEXMETHYLPHENIDATES:

**FOCALIN (ALL PRODUCTS)
(dexamethylphenidate)**

DEXTROAMPHETAMINES:

**DEXEDRINE (ALL PRODUCTS)
(dextroamphetamine)**

(dextroamphetamine) (ALL PRODUCTS)

**PROCENTRA (ALL PRODUCTS)
(dextroamphetamine)**

ADHD Agents Post Limit 1218-J, 683-J11.2017

CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members.

CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc. CareFirst of Maryland, Inc., Group Hospitalization and Medical Services, Inc., CareFirst BlueChoice, Inc., The Dental Network and First Care, Inc. are independent licensees of the Blue Cross and Blue Shield Association. In the District of Columbia and Maryland, CareFirst MedPlus is the business name of First Care, Inc. In Virginia, CareFirst MedPlus is the business name of First Care, Inc. of Maryland (used in VA by: First Care, Inc.). © Registered trademark of the Blue Cross and Blue Shield Association

**ZENZEDI (ALL PRODUCTS)
(dextroamphetamine)**

LISDEXAMFETAMINES:

**VYVANSE (ALL PRODUCTS)
(lisdexamfetamine)**

METHAMPHETAMINES:

**DESOXYN (ALL PRODUCTS)
(methamphetamine)**

METHYLPHENIDATES:

**APTENSIO (ALL PRODUCTS)
(methylphenidate)**

**CONCERTA (ALL PRODUCTS)
(methylphenidate)**

**COTEMPLA (ALL PRODUCTS)
(methylphenidate)**

**DAYTRANA (ALL PRODUCTS)
(methylphenidate)**

**METADATE (ALL PRODUCTS)
(methylphenidate)**

**METHYLIN (ALL PRODUCTS)
(methylphenidate)**

(methylphenidate) (ALL PRODUCTS)

**QUILLICHEW (ALL PRODUCTS)
(methylphenidate)**

**QUILLIVANT (ALL PRODUCTS)
(methylphenidate)**

**RITALIN (ALL PRODUCTS)
(methylphenidate)**

**SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS:
STRATTERA (ALL PRODUCTS)**

(atomoxetine)

Status: CVS Caremark Criteria

Type: Post Limit Prior Authorization

POLICY

FDA-APPROVED INDICATIONS

Adderall XR, Aptensio XR, Daytrana, Dyanavel XR, Focalin, Metadate CD, QuilliChew ER, Quillivant XR, Ritalin LA, Strattera

Adderall XR, Aptensio XR, Daytrana, Dyanavel XR, Focalin, Metadate CD, QuilliChew ER, Quillivant XR, Ritalin LA, and Strattera are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Concerta, Methylphenidate Osmotic Extended-Release

Concerta and Methylphenidate Extended-Release is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children 6 years of age and older, adolescents, and adults up to the age of 65.

Adzenys ER, Adzenys XR-ODT, Focalin XR

Adzenys ER, Adzenys XR-ODT, and Focalin XR are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

Cotempla XR-ODT

Cotempla XR-ODT is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.

Mydayis

Mydayis is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 13 years and older.

Adderall, Dexedrine Spansule, Dextroamphetamine, Methylin Chewable Tablets, Methylphenidate, Methylphenidate Extended-Release, ProCentra, Zenzedi,

Adderall, Dexedrine Spansules, Dextroamphetamine, Methylin Chewable Tablets, methylphenidate, methylphenidate extended-release, ProCentra, Zenzedi are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy.

Desoxyn

Desoxyn is indicated for Attention Deficit Disorder with Hyperactivity and Exogenous Obesity.

Evekeo

Evekeo is indicated for Narcolepsy, Attention Deficit Disorder with Hyperactivity, and Exogenous Obesity.

Vyvanse

Vyvanse is indicated for the treatment of:

- Attention Deficit Hyperactivity Disorder (ADHD)
- Moderate to Severe Binge-Eating Disorder (BED) in adults

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The patient has a diagnosis of Attention-Deficit Hyperactivity Disorder (ADHD) or Attention Deficit Disorder (ADD) **AND**
- The diagnosis has been appropriately documented (i.e., evaluated by a complete clinical assessment, using DSM-5, standardized rating scales, interviews/questionnaires).

OR

- The patient has a diagnosis of narcolepsy confirmed by a sleep study **AND**
- This request is NOT for amphetamine extended-release (Adzenys ER, Adzenys XR-ODT), amphetamine extended-release mixture (Adderall XR, Mydayis), methylphenidate chewable tablet (Methylin chewable tablet), methylphenidate immediate release, methylphenidate extended-release (Aptensio XR, Concerta, Cotempla XR-ODT, Metadate CD, Methylphenidate Osmotic Extended-Release, QuilliChew ER, Quillivant XR, Ritalin LA), dexamethylphenidate (Focalin), or dexamethylphenidate extended-release (Focalin XR)

REFERENCES

1. Adderall [package insert]. North Wales, PA: Teva Pharmaceuticals USA; September 2016.
2. Adderall XR [package insert]. Lexington, MA: Shire LLC.; January 2017.
3. Adzenys ER [package insert]. Grand Prairie, TX: Neos Therapeutics, LP.; September 2017.
4. Adzenys XR-ODT [package insert]. Grand Prairie, TX: Neos Therapeutics, LP.; October 2016.
5. Aptensio XR [package insert]. Coventry, RI: Rhodes Pharmaceuticals L.P.; October 2016.
6. Concerta [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; January 2017.
7. Cotempla XR-ODT [package insert]. Grand Prairie, TX: Neos Therapeutics, Inc.; June 2017.
8. Daytrana [package insert]. Miami, FL: Noven Therapeutics, LLC; January 2017.
9. Desoxyn [package insert]. Lebanon, NJ: Recordati Rare Diseases Inc.; May 2017.
10. Dexedrine Spansule [package insert]. Horsham, PA: Amedra Pharmaceuticals, LLC; March 2017.
11. Dextroamphetamine sulfate [package insert]. Newtown, PA: KVK-Tech, Inc.; January 2017.
12. Dyanavel XR [package insert]. Monmouth Junction, NJ: Tris Pharma, Inc.; May 2017.
13. Evekeo [package insert]. Atlanta, GA: Arbor Pharmaceuticals, LLC; September 2016.
14. Focalin [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2017.
15. Focalin XR [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2017.
16. Metadate CD [package insert]. Smyrna, GA: UCB, Inc.; October 2016.
17. Metadate ER [package insert]. Smyrna, GA: UCB, Inc.; February 2017.
18. Methylin Solution [package insert]. Florham Park, NJ: Shionogi Inc.; September 2016.
19. Methylphenidate/Methylphenidate ER Tablets [package insert]. Hazelwood, MO: Mallinckrodt Inc.; January 2017.
20. Methylphenidate Chewable Tablets [package insert]. Baltimore, MD: Lupin Pharmaceuticals Inc.; May 2016.
21. Methylphenidate Osmotic Extended Release [package insert]. Bridgewater, NJ: Trigen Laboratories, LLC; November 2017.
22. Mydayis [package insert]. Lexington, MA: Shire US Inc.; June 2017.
23. ProCentra [package insert]. Newport, KY: Independence Pharmaceuticals, LLC; February 2017.
24. QuilliChew ER [package insert]. Monmouth Junction, NJ: Tris Pharma, Inc.; June 2017.
25. Quillivant XR [package insert]. Monmouth Junction, NJ: Tris Pharma, Inc.; June 2017.
26. Ritalin/Ritalin SR [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2017.
27. Ritalin LA [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2015.
28. Strattera [package insert]. Indianapolis, IN: Eli Lilly and Company; May 2017.
29. Vyvanse [package insert]. Wayne, PA: Shire US Inc.; July 2017.
30. Zenedi [package insert]. Atlanta, GA: Arbor Pharmaceuticals, LLC; February 2017.
31. AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; http://online.lexi.com/lco/action/index/dataset/complete_ashp [available with subscription]. Accessed November 2017.

32. Micromedex Solutions [database online]. Greenwood Village, CO: Truven Health Analytics Inc. Updated periodically. www.micromedexsolutions.com [available with subscription]. Accessed November 2017.
33. Morgenthaler TI, Vishesh KK, Brown T, et al. Practice Parameters for the Treatment of Narcolepsy and other Hypersomnias of Central Origin. *Sleep* 2007;30(12):1705-11.
34. American Academy of Pediatrics. ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. *Pediatrics*. 2011; 128(5):1007-1022. <http://pediatrics.aappublications.org/content/early/2011/10/14/peds.2011-2654>. Available at www.chadd.org. Accessed November 2017.
35. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA, American Psychiatric Association, 2013. Web. [dsm.psychiatryonline.org](http://www.dsm.psychiatryonline.org). Accessed November 2017.
36. Practice Parameter for the Assessment and Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. *J Am Acad Child Adolesc Psychiatry*. 2007; 46(7):894-921. <http://www.jaacap.com/article/S0890-8567%2809%2962182-1/pdf>. Available at www.chadd.org. Accessed November 2017.

Quantity Limit Chart for ADHD**		
Drug	Quantity/25 days*	Quantity/75 days*
Adderall 5 mg, 7.5 mg, 10 mg, 12.5 mg	120 tablets	360 tablets
Adderall 15 mg, 20 mg	90 tablets	270 tablets
Adderall 30 mg	60 tablets	180 tablets
Adderall XR 5 mg, 10 mg	120 capsules	360 capsules
Adderall XR 15 mg, 20 mg, 25 mg, 30 mg	60 capsules	180 capsules
Adzenys ER oral suspension 1.25 mg/ml	900 ml	2700 ml
Adzenys XR-ODT 3.1 mg, 6.3 mg, 9.4 mg	120 tablets	360 tablets
Adzenys XR-ODT 12.5 mg, 15.7 mg, 18.8 mg	60 capsules	180 capsules
Aptensio XR 10 mg, 15 mg, 20 mg, 30 mg**	90 capsules	270 capsules
Aptensio XR 40 mg, 50 mg**	60 capsules	180 capsules
Concerta 18 mg, 27 mg, 36 mg	90 tablets	270 tablets
Concerta 54 mg	60 tablets	180 tablets
Cotempla XR-ODT 8.6 mg, 17.3 mg	120 tablets	360 tablets
Cotempla XR-ODT 25.9 mg	90 tablets	270 tablets
Dextroamphetamine 2.5 mg, 5 mg, 7.5 mg, 10 mg	180 tablets	540 tablets
Dextroamphetamine 15 mg	120 tablets	360 tablets
Dextroamphetamine 20 mg	90 tablets	270 tablets
Dextroamphetamine 30 mg	60 tablets	180 tablets
Dexedrine Spansule 5 mg, 10 mg	150 capsules	450 capsules
Dexedrine Spansule 15 mg	120 capsules	360 capsules
Evekeo 5 mg, 10 mg	180 tablets	540 tablets
Focalin 2.5 mg, 5 mg, 10 mg	150 tablets	450 tablets
Focalin XR 5 mg, 10 mg, 15 mg**	90 capsules	270 capsules
Focalin XR 25 mg**	60 capsules	180 capsules

Metadate CD 10 mg, 20 mg, 30 mg**	90 capsules	270 capsules
Metadate CD 40 mg, 50 mg**	60 capsules	180 capsules
Methylin (methylphenidate) chewable tablets 2.5 mg, 5 mg, 10 mg	300 tablets	900 tablets
Methylphenidate 5 mg, 10 mg	210 tablets	630 tablets
Methylphenidate 20 mg	150 tablets	450 tablets
Methylphenidate oral solution 5 mg/5 ml	3,000 ml	9,000 ml
Methylphenidate oral solution 10mg/5ml	1,500 ml	4,500 ml
Methylphenidate ER 10 mg, 20 mg	150 tablets	450 tablets
Mydayis 12.5 mg**	90 capsules	270 capsules
ProCentra oral solution 5mg/5ml	1,800 ml	5,400 ml
QuilliChew ER 20 mg	150 tablets	450 tablets
QuilliChew ER 30 mg	90 tablets	270 tablets
QuilliChew ER 40 mg	60 tablets	180 tablets
Quillivant XR oral suspension 25 mg/5 mL (5 mg/1 ml)	600 ml	1,800 ml
Ritalin LA 10 mg, 20 mg**	150 capsules	450 capsules
Ritalin LA 30 mg**	90 capsules	270 capsules
Ritalin LA 40 mg**	60 capsules	180 capsules
Zenedi 2.5 mg, 5 mg, 7.5 mg, 10 mg	180 tablets	540 tablets
Zenedi 15 mg	120 tablets	360 tablets
Zenedi 20 mg	90 tablets	270 tablets
Zenedi 30 mg	60 tablets	180 tablets

**The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.*

** Aptensio XR 60 mg, Focalin XR 20mg, 30 mg, 35 mg, and 40 mg, Metadate CD 60 mg, Methylphenidate Osmotic Extended-Release 72 mg, Mydayis 25 mg, 37.5 mg, and 50 mg, Ritalin LA 60 mg strengths are not included in the post limit because a quantity that is greater than the initial limit would result in exceeding the off-label maximum daily dose.

***The initial limits for Daytrana, Desoxyn, Dyanavel XR, Strattera, and Vyvanse are set at the off-label maximum daily dose for ADHD or there is no established off-label maximum daily dosage; therefore, no post limit quantities will be available for these drugs for the diagnosis of ADHD.

Quantity Limit Chart for Narcolepsy**		
Drug	Quantity/25 days*	Quantity/75 days*
Adderall 5 mg, 7.5 mg, 10 mg, 12.5 mg	120 tablets	360 tablets
Adderall 15 mg, 20 mg	90 tablets	270 tablets
Adderall 30 mg	60 tablets	180 tablets
Dextroamphetamine 2.5 mg, 5 mg, 7.5 mg, 10 mg	180 tablets	540 tablets
Dextroamphetamine 15 mg	120 tablets	360 tablets
Dextroamphetamine 20 mg	90 tablets	270 tablets
Dextroamphetamine 30 mg	60 tablets	180 tablets
Dexedrine Spansule 5 mg, 10 mg	150 capsules	450 capsules
Dexedrine Spansule 15 mg	120 capsules	360 capsules
Evekeo 5 mg, 10 mg	180 tablets	540 tablets
ProCentra oral solution 5mg/5ml	1,800 ml	5,400 ml

Zenedi 2.5 mg, 5 mg, 7.5 mg, 10 mg	180 tablets	540 tablets
Zenedi 15 mg	120 tablets	360 tablets
Zenedi 20 mg	90 tablets	270 tablets
Zenedi 30 mg	60 tablets	180 tablets
<i>*The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.</i>		

**The initial limits for methylphenidate, methylphenidate extended-release, and Methylin chewable tablets are set at the FDA maximum approved daily doses for narcolepsy; therefore, no post limit quantities will be available for these drugs for the diagnosis of narcolepsy.